Evidence map›Paper›PMID 26780740›Full record

ReviewJournal of thrombosis and thrombolysis2016

Guidance for the prevention and treatment of cancer-associated venous thromboembolism.

Alok A Khorana, Marc Carrier, David A Garcia, Agnes Y Y Lee

Abstract readReview
In one paragraph

Review in Journal of thrombosis and thrombolysis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. The effectiveness and safety of thromboprophylaxis in cancer patients based on Khorana score: a meta-analysis and systematic review of randomized controlled trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Development and Validation of a Risk Score for Prediction of Venous Thromboembolism in Patients With Lung Cancer.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Time to move beyond risk assessment models for ambulatory cancer-associated thrombosis.Research and practice in thrombosis and haemostasis · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Alok A KhoranaTaussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, 9500 Euclid Ave, R35, Cleveland, OH, 44195, USA. khorana@ccf.org.
Marc CarrierDepartment of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
David A GarciaDivision of Hematology, University of Washington School of Medicine, Seattle, WA, USA.
Agnes Y Y LeeDepartment of Medicine, Thrombosis Program, University of British Columbia and Vancouver Coastal Health Authority, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venous thromboembolism (VTE) is a highly prevalent complication of malignancy with emerging changes in incidence, diagnosis and treatment paradigms. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. We address a) the appropriate workup to search for occult malignancy in patients with idiopathic VTE, b) identification of high-risk cancer patients for primary thromboprophylaxis, c) the appropriate immediate and long-term treatment for people with cancer diagnosed with acute thromboembolism, d) the appropriate duration of anticoagulation and e) the appropriate treatment strategy in patients with recurrent VTE on anticoagulation. Areas of controversy and future directions in this field are highlighted.

Indexed as

Administration, OralAnticoagulantsHumansNeoplasmsPractice Guidelines as TopicVenous ThromboembolismAnticoagulantsCancerDirect oral anticoagulants (DOAC)New oral anticoagulants (NOAC)PreventionRisk factorsVenous thromboembolism

Identifiers

PMID26780740
PMCPMC4715852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.